A Randomized Trial Evaluating the Association Between Related Gene Polymorphism and Nausea and Vomiting Induced by Cisplatin Multi-day Chemotherapy

Overview

Journal BMC Med Genomics

Publisher Biomed Central

Specialty Genetics

Date 2023 Nov 4

PMID 37924126

Authors

Yilan Jin

Feng Chen

Juan Zhao

Ying Jiang

Gaowa Jin

Zewei Zhang

Quanfu Li

Affiliations

Soon will be listed here.

Abstract

Purpose: We aim to investigate the correlation between gene polymorphisms and cisplatin chemotherapy-induced nausea and vomiting (CINV), which was prevented by olanzapine or aprepitant triple antiemetic regimen.

Methods: Before chemotherapy, the blood samples of 89 malignant tumor patients who received multi-day chemotherapy with cisplatin were collected for sequencing and typing. As there were duplicate patients enrolled in different chemotherapy cycles, there were a total of 190 cases. The patients were divided into two groups randomly, who received the triple antiemetic regimen of olanzapine or aprepitant combined with 5-HT3RA and dexamethasone. The main evaluation indicators were the total protection (TP) rate in the acute phase (0-24 h), the delayed phase (25-120 h) and the overall phase (0-120 h).

Results: Univariate analysis was performed on genetic loci that reached H-W balance with TP. In the olanzapine group, increased TP in the acute phase was associated with HTR3A rs1176719 non-GG (P < 0.05) genotype etc. Increased TP in the delayed phase was associated with HTR3A rs1176719 non-GG (P < 0.05) genotype etc. In the aprepitant group, increased TP in the acute phase was associated with the MTHFR rs1801131 TT (P < 0.05) genotype etc. Increased TP in the delayed phase was associated with HTR3A rs1062613 CC (P < 0.05) genetype ect. Multivariate Logistic regression analysis showed that HTR3B rs7943062GG (P < 0.05) genotype etc. were correlated with increased TP in the delayed phase. MTHFR rs1801131TT genotype was associated with increased TP in the acute phase (P < 0.05) and delayed phase (P < 0.05).

Conclusion: This study found that gene polymorphisms, including HTR3B (rs1062613, rs1176719, rs2276303), HTR3B (rs45460698, rs7943062), HTR3C (rs6766410), ERCC1 (rs3212986), ERCC4 (rs744154) and MTHFR(rs1801131), may be independent prognostic factors for CINV.

Citing Articles

A prospective randomized controlled clinical trial investigating the efficacy of low-dose olanzapine in preventing nausea and vomiting associated with oxaliplatin-based and irinotecan-based chemotherapy.

Shen J, Zhao J, Jin G, Li H, Jiang Y, Wu Y J Cancer Res Clin Oncol. 2024; 150(5):283.

PMID: 38806870 PMC: 11133208. DOI: 10.1007/s00432-024-05712-7.

References

Ward M, Kotasek D, McKinnon R . Investigation of HTR3C mutations for association with 5HT(3) receptor antagonist anti-emetic efficacy. Pharmacogenomics. 2008; 9(8):1027-33. DOI: 10.2217/14622416.9.8.1027. View

De Rienzo F, Del Cadia M, Menziani M . A first step towards the understanding of the 5-HT3 receptor subunit heterogeneity from a computational point of view. Phys Chem Chem Phys. 2012; 14(36):12625-36. DOI: 10.1039/c2cp41028a. View

Wheeler H, Gamazon E, Stark A, ODonnell P, Gorsic L, Huang R . Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations. Pharmacogenomics J. 2011; 13(1):35-43. PMC: 3370147. DOI: 10.1038/tpj.2011.38. View

Kang G, Kim K, Shim H, Hwang J, Bae W, Chung I . Effect of the allelic variants of ABCB1, CYP2D6 and HTR3B on response of ramosetron to prevent chemotherapy-induced nausea and vomiting in Korean cancer patients. Asia Pac J Clin Oncol. 2016; 13(1):53-60. DOI: 10.1111/ajco.12575. View

Krzywkowski K, Davies P, Feinberg-Zadek P, Brauner-Osborne H, Jensen A . High-frequency HTR3B variant associated with major depression dramatically augments the signaling of the human 5-HT3AB receptor. Proc Natl Acad Sci U S A. 2008; 105(2):722-7. PMC: 2206603. DOI: 10.1073/pnas.0708454105. View

Niesler B, Kapeller J, Hammer C, Rappold G . Serotonin type 3 receptor genes: HTR3A, B, C, D, E. Pharmacogenomics. 2008; 9(5):501-4. DOI: 10.2217/14622416.9.5.501. View

Fasching P, Kollmannsberger B, Strissel P, Niesler B, Engel J, Kreis H . Polymorphisms in the novel serotonin receptor subunit gene HTR3C show different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy. J Cancer Res Clin Oncol. 2008; 134(10):1079-86. DOI: 10.1007/s00432-008-0387-1. View

Lee A, Shi Q, Pavey E, Alberts S, Sargent D, Sinicrope F . DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). J Natl Cancer Inst. 2014; 106(12). PMC: 4271081. DOI: 10.1093/jnci/dju298. View

Soefje S . Strategies to improve CINV outcomes in managed care. Am J Manag Care. 2018; 24(18 Suppl):S398-S404. View

10.

Jin Y, Jin G, Zhao J, Jiang C, Zhao L, Jiang Y . Clinical Observation of Gene Polymorphism of Olanzapine or Aprepitant in Prevention of CINV. Pharmgenomics Pers Med. 2021; 14:867-875. PMC: 8289460. DOI: 10.2147/PGPM.S317229. View

11.

Yokoi M, Tsuji D, Suzuki K, Kawasaki Y, Nakao M, Ayuhara H . Genetic risk factors for chemotherapy-induced nausea and vomiting in patients with cancer receiving cisplatin-based chemotherapy. Support Care Cancer. 2017; 26(5):1505-1513. DOI: 10.1007/s00520-017-3974-3. View

12.

Lehmann A, Renbarger J, McCormick C, Topletz A, Rouse C, Haas D . Pharmacogenetic predictors of nausea and vomiting of pregnancy severity and response to antiemetic therapy: a pilot study. BMC Pregnancy Childbirth. 2013; 13:132. PMC: 3693967. DOI: 10.1186/1471-2393-13-132. View

13.

Pud D, Har-Zahav G, Laitman Y, Rubinek T, Yeheskel A, Ben-Ami S . Association between variants of 5-hydroxytryptamine receptor 3C (HTR3C) and chemotherapy-induced symptoms in women receiving adjuvant treatment for breast cancer. Breast Cancer Res Treat. 2014; 144(1):123-31. DOI: 10.1007/s10549-014-2832-y. View

14.

Perwitasari D, Wessels J, van der Straaten R, Baak-Pablo R, Mustofa M, Hakimi M . Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy. Jpn J Clin Oncol. 2011; 41(10):1168-76. DOI: 10.1093/jjco/hyr117. View

15.

Schulz K, Altman D, Moher D . [CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials (Chinese version)]. Zhong Xi Yi Jie He Xue Bao. 2010; 8(7):604-12. DOI: 10.3736/jcim20100702. View

16.

Tremblay P, Kaiser R, Sezer O, Rosler N, Schelenz C, Possinger K . Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. J Clin Oncol. 2003; 21(11):2147-55. DOI: 10.1200/JCO.2003.05.164. View

17.

Tzvetkov M, Saadatmand A, Bokelmann K, Meineke I, Kaiser R, Brockmoller J . Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5-HT(3) antagonists tropisetron and ondansetron. Pharmacogenomics J. 2010; 12(1):22-9. DOI: 10.1038/tpj.2010.75. View

18.

Kitamura T, Qian B, Soong D, Cassetta L, Noy R, Sugano G . CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages. J Exp Med. 2015; 212(7):1043-59. PMC: 4493415. DOI: 10.1084/jem.20141836. View

19.

Kapeller J, Houghton L, Monnikes H, Walstab J, Moller D, Bonisch H . First evidence for an association of a functional variant in the microRNA-510 target site of the serotonin receptor-type 3E gene with diarrhea predominant irritable bowel syndrome. Hum Mol Genet. 2008; 17(19):2967-77. DOI: 10.1093/hmg/ddn195. View

20.

Oliva D, Nilsson M, Andersson B, Sharp L, Lewin F, Laytragoon-Lewin N . Single nucleotide polymorphisms might influence chemotherapy induced nausea in women with breast cancer. Clin Transl Radiat Oncol. 2018; 2:1-6. PMC: 5893496. DOI: 10.1016/j.ctro.2016.12.001. View